These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Proliferative activity and p53 over-expression of ovarian epithelial tumors. Kuwata T; Kitagawa M; Takemura T; Hirokawa K Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593 [TBL] [Abstract][Full Text] [Related]
3. Quantification of p53 in epithelial ovarian cancer. Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258 [TBL] [Abstract][Full Text] [Related]
4. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters]. Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599 [TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797 [TBL] [Abstract][Full Text] [Related]
6. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106 [TBL] [Abstract][Full Text] [Related]
7. [Expression of p21(WAF1) and its relationship with p53 and PCNA protein in epithelial ovarian cancer]. Yan XJ; Liang LZ; Li DC; Li JL; Zhang CQ; Yuan SH Ai Zheng; 2004 Jan; 23(1):74-80. PubMed ID: 14720380 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic pitfalls of peritoneal washing cytology and the role of cell blocks in their diagnosis. Selvaggi SM Diagn Cytopathol; 2003 Jun; 28(6):335-41. PubMed ID: 12768641 [TBL] [Abstract][Full Text] [Related]
9. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Ferrandina G; Fagotti A; Salerno MG; Natali PG; Mottolese M; Maneschi F; De Pasqua A; Benedetti-Panici P; Mancuso S; Scambia G Br J Cancer; 1999 Oct; 81(4):733-40. PubMed ID: 10574264 [TBL] [Abstract][Full Text] [Related]
10. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751 [TBL] [Abstract][Full Text] [Related]
11. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Brustmann H Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981 [TBL] [Abstract][Full Text] [Related]
12. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
14. p53 immunostaining as a marker of malignancy in cytologic preparations of body fluids. Tiniakos DG; Healicon RM; Hair T; Wadehra V; Horne CH; Angus B Acta Cytol; 1995; 39(2):171-6. PubMed ID: 7887063 [TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Boonsong A; Curran S; McKay JA; Cassidy J; Murray GI; McLeod HL Hum Pathol; 2002 Nov; 33(11):1114-9. PubMed ID: 12454816 [TBL] [Abstract][Full Text] [Related]
16. Relations between immunologically different p53 forms, p21(WAF1) and PCNA expression in ovarian carcinomas. Harlozinska A; Bar JK; Montenarh M; Kartarius S Oncol Rep; 2002; 9(6):1173-9. PubMed ID: 12375014 [TBL] [Abstract][Full Text] [Related]
17. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Vogl FD; Frey M; Kreienberg R; Runnebaum IB Br J Cancer; 2000 Nov; 83(10):1338-43. PubMed ID: 11044359 [TBL] [Abstract][Full Text] [Related]
19. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189 [TBL] [Abstract][Full Text] [Related]
20. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]